Background: To describe chemotherapy treatment patterns and clinical outcomes in metastatic soft tissue sarcoma (mSTS) patients with favorable response to chemotherapy.
introduction Soft-tissue sarcomas (STSs) are malignant tumors of connective tissue, accounting for ∼1% of all human cancers [1] . There are >50 different histological subtypes of STS, with leiomyosarcoma and liposarcoma as the most common subtypes [1] . The annual incidence of STS ranges from 2.4 to 3.6 new cases per 100 000 in population-based studies [2] [3] [4] . Approximately 50% of patients diagnosed with STS are diagnosed with or expected to progress to metastatic disease (mSTS) [4, 5] .
Surgery is the standard primary management for patients with resectable STS, except for those who present with metastatic disease who may simply receive chemotherapy. Radiotherapy is used routinely as adjuvant treatment for patients with intermediate to high-grade tumors, having been shown to improve local disease control. The value of adjuvant or neoadjuvant chemotherapy remains a subject of considerable debate [6] . Guidelines recommend first-line anthracycline-based (with or without ifosfamide) chemotherapy as the standard of care for mSTS patients, with trabectedin, gemcitabine with or without docetaxel, and dacarbazine reserved for second or later lines of treatment [6] [7] [8] . Furthermore, it is now recognized that the choice of chemotherapy may be adapted to the site of the disease and histological or molecular subtype [9] . For example, paclitaxel appears to have specific efficacy in angiosarcomas and gemcitabine, with or without docetaxel, and is active against leiomyosarcoma, especially uterine [10] [11] [12] . Trabectedin has a high level of activity in leiomyosarcoma and liposarcoma, in particular myxoid liposarcoma [13, 14] .
While there is considerable literature from clinical trials on the outcomes associated with specific treatments in mSTS, there is limited observational data to describe the outcomes of real-life clinical practice in patients with mSTS treated with chemotherapy [15, 16] . The rationale for this study was to understand the treatment patterns and outcomes of mSTS patients with favorable response to chemotherapy across a range of countries.
patients and methods

study design
The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study was a multi-country, multisite retrospective chart review and cross-sectional patient survey conducted in nine countries: Canada, France, Germany, Italy, The Netherlands, Spain, Sweden, UK, and United States. The chart review portion of SABINE is presented here, while the patient survey is published elsewhere [17] . Patient data were collected from initiation of first-line chemotherapy, between January 2004 and December 2009, to death or end of follow-up.
patients
Patients (age ≥13 years) with a confirmed diagnosis of metastatic STS, with one of the following subtypes: leiomyosarcoma, liposarcoma, synovial sarcoma, or undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma were included. Patients were also required to have favorable response within at least one line of chemotherapy, with favorable response defined as no disease progression documented by imaging before completion of fourth cycle of chemotherapy and favorable response (complete response, partial response, or stable disease, according to World Health Organisation or RECIST criteria) between start of the third cycle and discontinuation of the line of chemotherapy. Patients participating in the SUCCEED (Sarcoma MultiCenter Clinical Evaluation of the Efficacy of Ridaforolimus) trial were excluded [18] .
procedures
The study was approved by the local ethics committee at each site. Data collection forms were designed and collected detailed information on chemotherapy, reasons for discontinuation and modification, use of sarcoma-related imaging, and response status. Data on chemotherapy were collected by line of therapy, including number of cycles, drug name, and dose. For i.v. chemotherapies, the dates and places of administration were also collected. For oral chemotherapies, the start and stop dates and number of doses received were collected. The reasons for regimen discontinuation and the occurrence of and reasons for regimen modification, defined as dosage reduction or discontinuation of drug in a multidrug regimen, were collected within each line of chemotherapy. Sarcoma-related imaging was recorded, including type of imaging test, date imaging carried out, and response (complete response, partial response, stable disease, progressive disease, and not evaluated) for each imaging test.
To better describe the progression and treatment of disease over time, patient follow-up time was divided into mutually exclusive health states based on chemotherapy use and disease progression, within lines of therapy. Three mutually exclusive health states (on chemotherapy, off chemotherapy pre-progression, off chemotherapy post-progression) were defined within four lines of therapy (1, 2, 3, and 4+). The on chemotherapy period started the day of the first dose and ended 3 weeks after the last dose of chemotherapy, with the off chemotherapy period starting the following day and ending the day before the first dose of the next line of therapy. The off-chemotherapy period was divided into two periods-the time periods before and following disease progression ( pre-and postprogression), also within lines of therapy. The post-progression period started the date progressive disease was documented from an imaging result. Disease progression status was reset to 'pre-progression' with the first dose of a new line of therapy.
statistical analysis
The analysis of chemotherapy treatment patterns was descriptive, with analysis by line of therapy. The percentage of patients exceeding the recommended dose of doxorubicin (450 mg/m 2 ) or epirubicin (900 mg/ m 2 ), after which the risk of cardiotoxicity increases, was estimated [8, 19] .
The Kaplan-Meier product-limit estimator was used to determine the mean time spent in each state, until death or move to the next health state. In cases where the full survival curve was not observed (the last observation was censored), the curve was extrapolated using an exponential survival function. Mean time spent in each health state (for a patient entering this state) was multiplied by the lifetime probability of the patient entering the health state, yielding the expected time spent in the state. The lifetime probability was, in turn, calculated based on observed transitions between health states. Time-to-event analyses were conducted for overall survival (OS) and progression-free survival (PFS) using the Kaplan-Meier method, from the date first favorable response was attained, and stratified by line of therapy where favorable response was first observed. The date of favorable response was the date when four cycles of chemotherapy were completed. Additional time to event analyses was conducted from initiation of firstand second-line chemotherapy and from diagnosis of metastatic disease to allow for comparison to published literature. Patients who started a subsequent line of chemotherapy before progressing were not censored for PFS.
results
Patient demographic, clinical, and chemotherapy treatment characteristics are shown in Table 1 . Of the 213 assessable patients, 42% were male. Patients were treated at centers in France (29%), UK (14%), The Netherlands (14%), United States (13%), Spain (12%), Italy (8%), Germany (7%), Canada (3%), and Sweden (2%). The most frequent subtype was leiomyosarcoma (46%). The most common site of metastasis was lung (48%). The majority of patients (83%) achieved first favorable response during first-line chemotherapy. The percent of patients receiving second, third, and fourth lines of chemotherapy was 76%, 50%, and 25%, respectively. More than half of patients (56%) participated in clinical trials, and 63% were deceased at the time of chart abstraction.
chemotherapy treatment patterns
Chemotherapy use is presented in Table 2 . There were 59 different regimens taken by 213 patients in 585 lines of therapy. On average, patients received 2.7 lines of chemotherapy and 5.2 cycles (range: 1-42) per line. Across all lines of therapy, the most common regimen was doxorubicin original articles Annals of Oncology (n = 95), followed by trabectedin (n = 85), and docetaxel plus gemcitabine (n = 67).
Doxorubicin monotherapy was the most common regimen in first line (34%), followed by anthracycline (doxorubicin or epirubicin) plus ifosfamide (30%). In second line, docetaxel plus gemcitabine was the most common regimen (18%). Trabectedin was the most common regimen used in third and later lines. Treatment patterns also varied across countries. Most notably, doxorubicin alone was used less frequently in first line in the United States (1 of 27 patients), Germany ( 
favorable response to chemotherapy
The number of patients with and without favorable response by cycle is shown in Figure 1 . A total of 585 lines of chemotherapy were analyzed, with 314 having favorable response (54%). Favorable response was achieved by 83% of time spent in health states Figure 2 shows the mean number of expected weeks per health state. The results highlight the longer time spent off chemotherapy pre-progression following first-line chemotherapy (38 weeks) than second line (5.6 weeks), third line (6.4 weeks), and fourth or later lines (2.7 weeks).
reasons for chemotherapy discontinuation
The primary reason for chemotherapy discontinuation in first and second or later lines for those patients who respond favorably is shown in Table 3 . In first line, a planned number of cycles given was the most common reason for discontinuation (64%). In second or later lines, disease progression was the most common reason (41%). Anthracyclines alone or in combination were more commonly discontinued due to planned number of cycles given in first line (70% and 71%, respectively) compared with other regimens (20%-57%). Trabectedin was the regimen most frequently associated with discontinuation due to disease progression (60% in first line and 53% second or later lines). Supplemental Table S3 (available at Annals of Oncology online) shows primary reason for discontinuation by country.
chemotherapy regimen modification
Chemotherapy was modified in 163 of 585 lines of therapy (28%), most commonly due to intolerable toxicity or adverse events (n = 126, 21%). The percent of patients who modified their chemotherapy regimen was consistent across lines of therapy (range: 23%-32%). Supplemental Table S4 (available at Annals of Oncology online) displays the incidence and reasons for regimen modification per line of treatment.
PFS and OS
Median PFS from first favorable response, across all lines, was 8.3 months [95% confidence interval (CI) 7.4-9.9]. The Kaplan-Meier plot for PFS from first favorable response, stratified by line, is displayed in Figure 3 . PFS for patients with first favorable response to first-line treatment was 8.7 months (95% CI 7.9-10.3), 6.6 months (95% CI 2.9-11.2) for second line, and 4.4 months (95% CI 0.8-13.3) for third-line chemotherapy.
Median OS from first favorable response, across all lines, was 23.5 months (95% CI 20.5-28.1). OS from first favorable response, stratified by line, is displayed in Figure 4 . Median OS from first favorable response to treatment was 26.1 months (95% CI 20.8-31.4) for first line, 23.8 months (95% CI 12.4-28.1) for second line, and 11.4 months (95% CI 4.1-22.3) for third line, respectively. These differences were statistically significant (P < 0.001). The median OS from diagnosis of metastatic disease was 33.3 months (95% CI 28.0-37.7), 28.9 from initiation of first-line therapy (95% CI 23.6-32.9), and 17.3 months (95% CI 13.1-19.7) from initiation of second line therapy.
discussion
Results from this study highlight that PFS and OS in mSTS patients with favorable response to chemotherapy were short. The median PFS and OS from first favorable response to chemotherapy were 8.3 and 23.5 months, respectively. Patients received multiple lines of chemotherapy (average of 2.7, range: 1-8), and the likelihood of favorable response was higher for first line compared with second or later lines of therapy. Distinct chemotherapy treatment patterns emerged for first line compared with second or later lines of therapy. Anthracyclines, with or without ifosfamide, were the dominant regimen in the first-line setting. The common reason for original articles Annals of Oncology discontinuation of first-line therapy, in lines where a favorable response was observed, was reaching a predefined number of cycles. The average time following first-line chemotherapy when patients were not receiving chemotherapy, but had yet to experience disease progression or start the next line of chemotherapy, was relatively long (38 weeks). In contrast, in second or later lines of therapy, no single dominant regimen emerged and disease progression was the most common reason for discontinuation in lines where a favorable response was observed. In second and later lines, the time period patients were off chemotherapy and prior to disease progression was short (2.7-5.6 weeks). Chemotherapy regimen modification was commonly used across all lines of therapy, with toxicity as the reason in a majority of cases. The OS from this study can be compared with the control ( placebo) arm of the SUCCEED clinical trial, with both studies having similar though not identical entry criteria. The median OS was 19.2 months in the control arm in the SUCCEED trial compared with 23.5 months from first favorable response to chemotherapy in this study [18] . OS statistics with different starting points were determined to compare with observational studies of patients with and without favorable response to chemotherapy [15, 16, 20] . In this study, the median OS was 33.3 months from metastatic disease diagnosis, 28.9 and 17.3 months from initiation of firstand second-line chemotherapy, respectively. Karavasilis et al. [15] estimated 45% of 488 mSTS patients treated at a UK tertiary care institution between 1991 and 2005 derived clinical benefit (stable disease or better for >6 months) from first-line palliative chemotherapy, with a median OS of 12 months from completion of first-line chemotherapy. Using data from the same institution and time period, Minchom et al. [16] reported that 22.7% of 379 patients derive clinical benefit from secondline chemotherapy, with a median OS of 8 months from initiation of second-line chemotherapy. Italiano et al. [20] reported that OS from mSTS diagnosis has improved by 50% during the last 20 years, most likely related to treatment, with a median OS of 18 months (95% CI 15.3-20.7) for 244 patients diagnosed at French Sarcoma Group centers from the most recent period (2002) (2003) (2004) (2005) (2006) . The longer OS in this study is supported by Reichardt et al. [21] , who reported a longer survival for patients with better responses to chemotherapy. Median OS by response type was 10 months for progressive disease, 17 months for stable disease, 25 months for partial response, and was not reached for complete response or no evidence of disease (after a median 33 months follow-up) [21] .
Chemotherapy regimens were generally consistent with those recommended in treatment guidelines. Anthracycline regimens, with or without ifosfamide, were the dominant regimen used for first-line therapy accounting for over 70% of utilization, consistent with guidelines where anthracyclines are recommended with the highest level and strength of evidence recommendation [6] . There were no dominant regimens in second or later lines, where lower levels of evidence and consensus for recommended therapies exist compared with first-line therapy [6] . Trabectedin alone was the most commonly used regimen in third through fifth lines of therapy (22%-28%), consistent with its sarcoma indication following failure of anthracyclines and ifosfamide.
From the analysis of time patients spend in each health state, we observed that patients were off chemotherapy in a stable disease or better health state for the longest time period following first-line chemotherapy compared with after second or later lines. This is expected given anthracyclines are most often discontinued when a pre-established number of cycles have been reached, and anthracyclines were used in a majority of first-line regimens. This time period, off cytotoxic chemotherapy and before disease progression, is when metastatic sarcoma patients experience a significantly better health-related quality. A recent cross section survey of 120 patients with metastatic soft tissue or bone sarcoma reported patients in stable disease or better and off chemotherapy had a quality of life score 25 points (out of 100 from the EORTC QLQ C30 overall health status scale, representing quality of life) higher than patients in progressive disease (P < 0.001) and 9, 16, and 20 points higher than patients currently treated with first (P = 0.14), second (P = 0.0092), or third line (P = 0.0054) chemotherapy, respectively [17] . In second and later lines of chemotherapy, patients were more commonly treated to disease progression and their disease remained controlled for a significantly shorter interval before progressing and/or receiving the next treatment.
Recently, maintenance therapy has emerged as a strategy to delay progression of disease in mSTS patients with favorable response (stable disease or better) to chemotherapy [18] . Based on results from this study, the number of patients anticipated original articles Annals of Oncology to benefit from maintenance therapy in mSTS is the greatest for those with favorable response to first-line chemotherapy, given first-line chemotherapy is more likely to be discontinued after a fixed number of cycles rather than due to disease progression. In addition, there is a higher likelihood of favorable response in the first line than in later lines and less attrition of patients as they progress through lines of therapy.
The major strength of this study is the detailed description of chemotherapy treatment patterns and clinical outcomes in real-life clinical practice across several countries. A study limitation was that approximately one-third of patients were alive at the time of chart abstraction, and some may have gone to receive additional chemotherapies not captured in the descriptive analysis of treatment patterns. Another potential limitation was that the analyses were mostly descriptive, which was necessitated by the sample size. A larger sample may have allowed an evaluation of the association of different treatment patterns with clinical outcomes.
This study highlights the significant unmet medical need in mSTS patients with favorable response to chemotherapy while also providing a description of contemporary treatment across a range of countries. Chemotherapy use is generally consistent with treatment guideline recommendations. The types of chemotherapy used, reasons for discontinuation, and the chemotherapy treatment-free period were quite distinct for first line as compared with second or later lines.
